Prospect

Researchers are evaluating the PAVE Parallactic Visual-Field Enhancement System for treating chronic visual field loss caused by stroke, traumatic brain injury, or brain surgery. This study focuses on patients with homonymous hemianopia, quadrantanopia, or general visual field constriction at least six months and up to ten years after brain injury. The goal is to measure improvement in visual field size and subjective visual function after PAVE therapy. The treatment involves using a virtual reality headset to deliver visual stimulation through the PAVE software. Participants will complete three therapy sessions per week for eight weeks, each session consisting of two seven-minute visual stimulation periods separated by a short break. The study includes baseline, mid-therapy week 4, end-of-therapy week 8, and follow-up week 12 visits for visual field assessments and questionnaires. Participants will visit the research office at the start, week 4, week 8, and week 12 for visual field measurements using Goldmann-type kinetic perimetry and to complete the National Eye Institute Visual Function Questionnaire. The study tracks changes in visual field area as the primary outcome and the proportion of participants showing improvement as a secondary outcome. The total participation duration is 12 weeks, including therapy and follow-up assessments.